PF-07248144 + PF-0722060 | Project advanced
Breast Cancer Metastatic
KAT6 Epigenetic modifier + CDK4 Inh
PF-07799544 | New project
Solid Tumors
MEK Brain Penetrant Inhibitor
PF-07220060 + enzalutamide | New project
Prostate Cancer
CDK4 inhibitor
PF-07104091 | New project
Ovarian Cancer
CDK2 inhibitor
PF-07799933 BRAF Class 2 | New project
Cancer
BRAF Class 1 and Class 2 inhibitor
PF-07104091 + PF-07220060 | New project
Breast Cancer Metastatic
CDK2 + CDK4 inhibitors
PF-07265028 | New project
Solid Tumors
HPK1 Inhibitor
PF-07260437 | New project
Breast Cancer Metastatic (Biologic)
B7H4-CD3 Bispecific
PF-07257876 | New project
NSCLC (Biologic)
CD47xPDL1 Bispecific
PF-07284892 | New project
Cancer
SHP2 tyrosine phosphatase Inhibitor
PF-07248144 | New project
Breast Cancer Metastatic
KAT6 Epigenetic modifier
PF-07104091 | New project
Breast Cancer Metastatic
CDK2 Inhibitor
PF-07265807 | New project
Solid Tumors
AXL/MERTK Inhibitor
PF-07220060 | New project
Breast Cancer Metastatic
CDK4 Inhibitor
PF-07209960 | New project
Solid Tumors (Biologic)
interleukin 15 (IL15) Activator
PF-06940434 | New project
Solid Tumors (Biologic)
Integrin alpha-V/beta-8 Antagonist
PF-07062119 | New project
Advanced/Metastatic Gastrointestinal Cancer (Biologic)
GUCY2c CD3 Bispecific Antibody
PF-06647020 | New project
NSCLC (Biologic)
PTK7 Targeted Cytotoxicity
PF-06821497 + enzalutamide | New project
Prostate Cancer
EZH2 Inhibitor
maplirpacept (TTI-622) | New project
Hematological Malignancies (Biologic)
CD47-SIRPa Fusion Protein
Vepdegestrant (ARV-471) | Project advanced
ER+/HER2- Early Breast Cancer
ER-targeting PROTAC® protein degrader
Ibrance + Vepdegestrant (ARV-471) | New project
ER+/HER2- Metastatic Breast Cancer
CDK 4,6 kinase inhibitor ER-targeting PROTAC® protein degrader
Vepdegestrant (ARV-471) | Project advanced
ER+/HER2- Metastatic Breast Cancer
ER-targeting PROTAC® protein degrader
Elranatamab | New project
Newly Diagnosed Multiple Myeloma Transplant-Ineligible (Biologic)
BCMA-CD3 Bispecific Antibody
Elranatamab | New project
Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (Biologic)
BCMA-CD3 Bispecific Antibody
Elranatamab | New project
Multiple Myeloma Double-Class Exposed (Biologic)
BCMA-CD3 Bispecific Antibody
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab) | New project
BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
BRAF kinase inhibitor andMEK inhibitor and anti PD-1
Braftovi (encorafinib) + Erbitux® (cetuximab) | New project
1st line BRAF-mutant Metastatic Colorectal Cancer
BRAF kinase inhibitor and anti EGFR
Xtandi (enzalutamide) | New project
Non-metastatic High-Risk Castration Sensitive Prostate Cancer
Androgen receptor inhibitor
Talzenna (talazoparib) | New project
Combo w/ Xtandi (enzalutamide) for DDR-deficient Metastatic Castration Sensitive Prostate Cancer
PARP inhibitor
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) | New project
Non-Muscle-Invasive Bladder Cancer (Biologic)
Anti-PD-1
Ibrance (palbociclib) | New project
ER+/HER2+ Metastatic Breast Cancer(PATINA)
CDK 4,6 kinase inhibitor
Talzenna (talazoparib) | Project advanced
Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration Resistant Prostate Cancer(PRIORITY REVIEW - U.S.)
PARP inhibitor
Braftovi (encorafinib) + Mektovi (binimetinib) | Project advanced
1st line BRAF-mutant Metastatic Non-Small Cell Lung Cancer
BRAF kinase inhibitor andMEK inhibitor
Elranatamab | Project advanced
Multiple Myeloma Triple-Class Refractory (Biologic) (BREAKTHROUGH, FAST TRACK, ORPHAN - U.S.) (ORPHAN, PRIME - EU)
BCMA-CD3 Bispecific Antibody